Translocator Protein Distribution Volume Predicts Reduction of Symptoms During Open-Label Trial of Celecoxib in Major Depressive Disorder

Authors:

Abstract
No abstract available
Funding Information
  • Jazz Pharmaceuticals (NCT02362529)
  • Canadian Institutes of Health Research
  • National Institutes of Health
  • Canada Foundation for Innovation
  • National Institute on Drug Abuse (DA04066)
  • Canada Research Chairs (GSD-157948, MOP-136955)
  • Azrieli Foundation
  • Janssen Pharmaceutica
  • Brain and Behavior Research Foundation

This publication has 43 references indexed in Scilit: